Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Sarcoma Research
Published in: Clinical Sarcoma Research 1/2018

Open Access 01-12-2018 | Research

Periostin expression in neoplastic and non-neoplastic diseases of bone and joint

Authors: Jennifer M. Brown, Akiro Mantoku, Afsie Sabokbar, Udo Oppermann, A. Bass Hassan, Akiro Kudo, Nick Athanasou

Published in: Clinical Sarcoma Research | Issue 1/2018

Login to get access

Abstract

Background

Periostin is a matricellular protein that is expressed in bone and joint tissues. To determine the expression of periostin in primary bone tumours and to assess whether it plays a role in tumour progression, we carried out immunohistochemistry and ELISA for periostin in a range of neoplastic and non-neoplastic bone and joint lesions.

Methods

140 formalin-fixed paraffin-embedded sections of bone tumours and tumour-like lesions were stained by an indirect immunoperoxidase technique with a polyclonal anti-periostin antibody. Periostin expression was also assessed in rheumatoid arthritis (RA) and non-inflammatory osteoarthritis (OA) synovium and synovial fluid immunohistochemistry and ELISA respectively.

Results

Periostin was most strongly expressed in osteoid/woven bone of neoplastic and non-neoplastic bone-forming lesions, including osteoblastoma, osteosarcoma, fibrous dysplasia, osteofibrous dysplasia, fracture callus and myositis ossificans, and mineralised chondroid matrix/woven bone in chondroblastoma and clear cell chondrosarcoma. Reactive host bone at the edge of growing tumours, particularly in areas of increased vascularity and fibrosis, also stained strongly for periostin. Vascular elements in RA synovium strongly expressed periostin, and synovial fluid levels of periostin were higher in RA than OA.

Conclusions

In keeping with its known role in modulating the synthesis of collagen and other extracellular matrix proteins in bone, strong periostin expression was noted in benign and malignant lesions forming an osteoid or osteoid-like matrix. Periostin was also noted in other bone tumours and was found in areas of reactive bone and increased vascularity at the edge of growing tumours, consistent with its involvement in tissue remodelling and angiogenesis associated with tumour progression.
Literature
1.
Takeshita S, Kikuno R, Tezuka K, Amann E. Osteoblast-specific factor 2: cloning of putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J. 1993;294:271–8.CrossRefPubMedPubMedCentral
2.
Horiuchi K, Amizuka N, Takeshita S, et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res. 1999;14:1239–49.CrossRefPubMed
3.
4.
Merie B, Garnero P. The multiple facets of periostin in bone metabolism. Osteoporos Int. 2012;23:1199–212.CrossRef
5.
Cobo T, Voloria CG, Solares L, Fontanil T, Gonzales-Chanorro E, De Carlos F, Cobo JM, Cal S, Obaya AJ. Role of periostin in adhesion and migration of bone remodelling cells. PLoS ONE. 2016;11:e0147837.CrossRefPubMedPubMedCentral
6.
Conway SJ, Izuhara K, Kudo Y, Litvin J, Markwald R, Ouyang G, Arron JR, Holeweg CT, Kudo A. The role of periostin in tissue remodelling across health and disease. Cell Mol Life Sci. 2014;71:1279–88.CrossRefPubMed
7.
8.
Kasperkovitz PV, Timmer TC, Smeets TJ, et al. Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis. Arthritis Rheum. 2005;52:430–41.CrossRefPubMed
9.
Geyer M, Grassel S, Straub RH, et al. Differential transcriptome analysis of intra-articular lesional vs intact cartilage reveals new candidate genes in osteoarthritis pathophysiology. Osteoarthritis Cartilage. 2009;17:328–35.CrossRefPubMed
10.
You S, Yoo SA, Choi S, et al. Identification of key regulators for the migration and invasion of rheumatoid synoviocytes through a systems approach. Proc Natl Acad Sci USA. 2014;111(550–555):11.
11.
Ye D, Shen ZS, Qiu SJ, Li Q, Wang GL. Role and underlying mechanisms of the interstitial protein periostin in the diagnosis and treatment of malignant tumours. Oncol Lett. 2017;14:5099–106.PubMedPubMedCentral
12.
Ratajczak-Wielgomas K, Dziegiel P. The role of periostin in neoplatic processes. Folia hitiochem Cytobiol. 2015;53:120–32.CrossRef
13.
Kashima TG, Nishiyama T, Shimazu K, et al. Periostin, a novel marker of intramembranous ossification, is expressed in fibrous dysplasia and in c-Fos-overexpressing bone lesions. Hum Pathol. 2009;40:226–37.CrossRefPubMed
14.
Hu F, Wang W, Zhou HC, Shang XF. High expression of periostin is dramatically associated with metastatic potential and poor prognosis of patients with osteosarcoma. World J Surg Oncol. 2014;12:287.CrossRefPubMedPubMedCentral
15.
Hu F, Shang XF, Wang W, Jiang W, Fang C, Tan D, Zhou HC. High expression of periostin is significantly correlated with tumour angiogenesis and poor prognosis in osteosarcoma. Int J Exp Pathol. 2016;97(1):86–92.CrossRefPubMedPubMedCentral
16.
Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone. 4th ed. IARC: Lyon; 2013.
17.
Kikuchi Y, Kashima TG, Nishiyama T, et al. Periostin is expressed in pericryptal fibroblasts and cancer-associated fibroblasts in the colon. J Histochem Cytochem. 2008;56:753–64.CrossRefPubMedPubMedCentral
18.
Maruhasi T, Kii I, Saito M, Kudo A. Interaction between periostin and BMP-1 promotes proteolytic activation of lysl oxidase. J Biol Chem. 2010;285:13294–303.CrossRef
19.
Kii I, Nishiyama T, Li M, Matumoto K, Saito M, Amizuka N, Kudo A. Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J Biol Chem. 2010;285:2028–39.CrossRefPubMed
20.
Bonnet N, Standley KN, Bianchi EN, Stadelmann V, Foti M, Conway SJ, Ferrari SL. The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity. J Biol Chem. 2009;284:35939–50.CrossRefPubMedPubMedCentral
21.
Athanasou NA, Bansai M, Forsyth R, Reid RP, Sapi Z. Giant cell tumour of bone. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC; 2013. p. 321–4.
22.
Lai X, Chen S. Identification of novel biomarker candidates for immunohistochemical diagnosis to distinguish low-grade chondrosarcoma from enchondroma. Proteomics. 2015;15:2358–68.CrossRefPubMed
23.
Mirra JM. Bone tumors: clinical radiological and pathological correlation. Philadelphia: Lee and Febiger; 1989.
24.
Kashima TG, Dongre A, Oppermann U, Athanasou NA. Dentine matrix protein (DMP-1) is a marker of bone-forming tumours. Virchows Arch. 2013;462(5):583–91.CrossRefPubMed
25.
Inagaki Y, Hookway ES, Kashima TG, Munemoto M, Tanaka Y, Hassan AB, Oppermann U, Athanasou NA. Sclerostin expression in bone tumours and tumour-like lesion. Histopathology. 2016;69:470–8.CrossRefPubMed
26.
Izuhara K, Nunomura S, Nanri Y, Ono J, Mitamura Y, Yoshihara T. Periostin in inflammation and allergy. Cell Mol Life Sci. 2017;74:4293–303.CrossRefPubMed
27.
Puglisi F, Puppin C, Pegolo E, Andreetta C, Pascoletti G, D’Aurizio F, Pandolfi M, Fasola G, Piga A, Damamte G, Di Loreto C. Expression of periostin in human breast cancer. J Clin Pathol. 2008;61:494–8.CrossRefPubMed
28.
Oh H, Bae JM, Wen XY, Chon Y, Kin JJ, Kang GH. Overexpression of periostin in tumour stroma is a poor prognostic indicator of colorectal cancer. J Pathol Trans Med. 2017;51:306–13.CrossRef
29.
Shao R, Bao S, Bai X, Blanchette C, Anderson RM, Dang T, Gishizky ML, Marks JR, Wang XF. Aquired expression of periostin by human breast cancer angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol. 2004;24:3992–4003.CrossRefPubMedPubMedCentral
30.
Fukushima N, Kikuchi Y, Nishiyama T, et al. Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas. Mod Pathol. 2008;21:1044–53.CrossRefPubMed
31.
Kikuchi Y, Kunita A, Iwata C, et al. The niche component periostin is produced by cancer-associated fibroblasts, supporting the growth of gastric cancer through ERK activation. Am J Pathol. 2014;184:859–70.CrossRefPubMed
32.
Tilman G, Mattiussi M, Brasseur F, van Baren N, Decottignies A. Human periostin gene expression in normal tissues, tumours and melanoma: evidence for periostin production by both stromal and melanoma cells. Mol Cancer. 2007;17(6):80.CrossRef
33.
Gillian L, Matei D, Fisherman DA, Gerbin CS, Karlan BY, Chang DD. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha (V) beta (3) and alpha (V) beta (5) integrins and promotes cell motility. Cancer Res. 2002;62:5358–64.
34.
Litvin J, Chen X, Keleman S, Zhu S, Autleri M. Expression and function of periostin-like factor in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2007;292:C1672–80.CrossRefPubMed
35.
Kim BR, Kwon YW, Park GT, Choi EJ, Seo JK, Jang IH, Kim SC, Ko HC, Lee SC, Kim JH. Identification of a novel angiogenic peptide from periostin. PLoS ONE. 2017;12(11):e0187464.CrossRefPubMedPubMedCentral
36.
Lu YI, Wang W, Jia WD, et al. High-level expression of periostin is closely related to metastatic potential and poor prognosis of hepatocellular carcinoma. Med Oncol. 2013;30:385.CrossRef
37.
Lindner V, Wang Q, Conley BA, Friesel RE, Vary CP. Vascular injury induces expression of periostin: implications for vascular cell differentiation and migration. Arterioscler Thromb Vasc Biol. 2005;25:77–83.PubMedCrossRef
38.
Kudo Y, Ogawa I, Kitajima S, et al. Periostin, a stroma-associated protein, correlates with tumour invasiveness and progression in nasopharyngeal carcinoma. Clin Exp Metastasis. 2012;29:865–77.CrossRef
39.
Contie S, Voorzanger-Rousselot N, Litvin J, Clezardin P, Garnero P. Increased expression and serum levels of the stromal cell protein periostin in breast cancer bone metastasis. Int J Cancer. 2011;128:352–60.CrossRefPubMed
40.
Bao S, Ouyang G, Bai X, et al. Perisotin potently promotes metastatic growth of colon cancer by augmenting cell survival via the AkT/PKB pathway. Cancer Cell. 2004;5:329–539.CrossRefPubMed
41.
Liu C, Huang SJ, Qin ZL. Inhibition of periostin gene expression via RNA suppressed the proliferation, apoptosis and invasion in U2OS cells. Chin Med J. 2010;123:3677–83.PubMed
Metadata
Title
Periostin expression in neoplastic and non-neoplastic diseases of bone and joint
Authors
Jennifer M. Brown
Akiro Mantoku
Afsie Sabokbar
Udo Oppermann
A. Bass Hassan
Akiro Kudo
Nick Athanasou
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Clinical Sarcoma Research / Issue 1/2018
Electronic ISSN: 2045-3329
DOI
https://doi.org/10.1186/s13569-018-0105-y

Other articles of this Issue 1/2018

Clinical Sarcoma Research 1/2018 Go to the issue

Meeting Report

Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma

Case report

Pleomorphic liposarcoma of bone: a rare primary malignant bone tumour

Research

Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas

Research

Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92

Research

Preoperative radiotherapy of soft-tissue sarcomas: surgical and radiologic parameters associated with local control and survival

Research

The use of whole exome sequencing and murine patient derived xenografts as a method of chemosensitivity testing in sarcoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits